UroGen Pharma (URGN) Interest & Investment Income (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Interest & Investment Income data on file, last reported at $608000.0 in Q1 2026.

• Quarterly Interest & Investment Income fell 71.24% year-over-year to $608000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 58.68% YoY) and the FY2025 annual result came in at $5.3 million, down 38.94% from the prior year.
• Interest & Investment Income slipped to $608000.0 in Q1 2026, from $903000.0 in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $2.8 million in Q4 2024 to a low of -$44000.0 in Q1 2022.
• A 5-year average of $1.1 million and a median of $906000.0 in 2023 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2022 — Interest & Investment Income surged 1930.0% — and 2026, when it sank 71.24%.
• Tracing URGN's Interest & Investment Income over 5 years: stood at $406000.0 in 2022, then surged by 278.82% to $1.5 million in 2023, then soared by 78.8% to $2.8 million in 2024, then slumped by 67.16% to $903000.0 in 2025, then tumbled by 32.67% to $608000.0 in 2026.
• The last three Interest & Investment Income figures came in at $608000.0 (Q1 2026), $903000.0 (Q4 2025), and $979000.0 (Q3 2025), per Business Quant data.